Browse the evidence

Indian populations have a higher susceptibility to type 2 diabetes at lower body mass indices (BMI) compared to global averages.

If you are of Indian descent, be aware that you may be at risk for diabetes even if you have a normal BMI. Prioritize regular screening and maintain a healthy lifestyle to manage risk factors.

Tirzepatide treatment in adults with obesity or overweight results in a body composition change where approximately 75% of total weight loss is fat mass and 25% is lean mass, a proportion consistent with placebo and other weight loss modalities.

If you take tirzepatide, expect to lose about 3 pounds of fat for every 1 pound of muscle. This is the same ratio you would get from dieting alone. You do not need to worry that the medication is uniquely damaging to your muscles. To protect your strength, focus on the recommended lifestyle changes: eat 500 calories less per day and move for 150 minutes a week.

Bariatric surgery (RYGB or SG) produces significantly greater weight loss and higher treatment success rates than structured medical treatment including very low energy diet (VLED) at 2-year follow-up, though both interventions improve cardiovascular risk factors and safety profiles similarly.

For individuals with BMI ≥35, bariatric surgery (RYGB or SG) is significantly more effective than structured medical treatment (including very low energy diets) for achieving substantial weight loss and metabolic improvement at 2 years. However, medical treatment remains a viable option that yields positive cardiovascular and safety outcomes, with about 45% of patients achieving >10% weight loss. The choice involves trading the higher efficacy of surgery for the non-invasiveness of medical management.

Baseline anthropometry (initial BMI/weight) is the strongest predictor of treatment success for both surgical and medical obesity interventions, followed by psychiatric health and lifestyle factors.

Your starting weight and BMI are the best predictors of how much weight you will lose, regardless of whether you choose surgery or medical treatment. Higher baseline BMI often correlates with greater absolute weight loss. Mental health and lifestyle habits are also significant factors.

Consuming two or more artificially sweetened beverages daily is associated with an elevated risk of all stroke and ischemic stroke in women.

Women should be aware that drinking two or more artificially sweetened beverages a day is linked to a higher risk of stroke. It is better to limit these drinks.

Higher diet quality attenuates the genetic predisposition for obesity, as measured by body mass index.

If you have a family history of obesity, eating a high-quality diet can help reduce the impact of your genes on your weight. Focus on the quality of your food.

Adherence to the Mediterranean Diet is associated with reduced risk of cognitive decline, dementia, and Alzheimer's disease, and improves cognitive function in older adults.

To protect your brain health as you age, follow a Mediterranean diet pattern rich in vegetables, fruits, nuts, olive oil, and fish. This way of eating has been linked to a lower risk of dementia and Alzheimer's disease and better cognitive function in older adults. It is a sustainable long-term strategy rather than a quick fix.

Current anti-obesity medications improve weight and metabolic parameters but do not yet have data supporting a reduction in hard cardiovascular outcomes.

While these drugs significantly reduce weight and improve metabolic markers, they have not yet been proven to reduce hard cardiovascular events like heart attacks or strokes. Weight loss itself is a key factor in long-term health.

High consumption of artificially sweetened beverages (ASBs) is associated with increased total and cardiovascular mortality, particularly in women, though substituting ASBs for SSBs may offer a modest mortality benefit.

If you consume high amounts of artificially sweetened beverages, consider reducing intake, especially if you are a woman. While replacing SSBs with ASBs reduces mortality risk compared to drinking SSBs, water remains the optimal choice for longevity.

High consumption of sugar-sweetened beverages (SSBs) in adulthood and adolescence is associated with a significantly increased risk of early-onset colorectal cancer (EO-CRC) in women.

For women, reducing sugar-sweetened beverage intake, especially during adolescence and adulthood, may help lower the risk of early-onset colorectal cancer. Substituting SSBs with coffee, milk, or artificially sweetened beverages is associated with a lower risk. While this study focuses on women, the metabolic mechanisms (insulin resistance, inflammation) suggest broader applicability, but more research is needed for men.

Obesity, particularly severe obesity (BMI ≥ 40 kg/m2), is an independent risk factor for severe complications and mortality from COVID-19, driven by increased prevalence of comorbidities like diabetes and hypertension, as well as physiological factors such as visceral fat storage.

If you have obesity, you are at higher risk for severe COVID-19 complications due to associated health conditions and physiological factors. Prioritize vaccination, follow public health guidelines strictly, and seek medical attention early if symptoms arise. Healthcare providers should treat you with respect and without bias.

Metformin increases circulating short-chain fatty acids (SCFAs), specifically acetate, butyrate, and valerate, at 6 months, which correlates with decreased fasting insulin, although these SCFA increases do not persist at 12 months.

Metformin boosts beneficial gut byproducts called short-chain fatty acids (SCFAs) like acetate and butyrate within the first 6 months, which is linked to better insulin control. However, this boost in SCFAs tends to fade after a year, even though the gut bacteria themselves remain changed. This suggests the body adapts to the higher SCFA levels, but the underlying microbial environment remains altered. This adaptation doesn't necessarily mean the drug stops working, but it highlights that the initial metabolic boost might be transient.

Sodium added to food outside the home (commercial processing and restaurant preparation) accounts for approximately 71% of total sodium intake in US adults, making it the primary source of dietary sodium.

To reduce sodium, focus on the food you buy and eat outside the home, not just the salt shaker. Check Nutrition Facts labels for packaged foods and ask for nutrition info when eating at restaurants. Reducing salt at the table is helpful but insufficient on its own because most sodium is already in processed and restaurant foods.

Sodium added to food outside the home is the leading source of sodium across all demographic subgroups, including variations by age, race, education, and geographic region.

No matter your background, most of your sodium comes from food bought or eaten outside your home. Focus on choosing lower-sodium packaged foods and making smarter choices at restaurants, as this is the most effective way to reduce sodium for everyone.

Clinical staging of obesity should utilize systems like the Edmonton Obesity Staging System (EOSS) or Waist Circumference (WC) thresholds, as BMI alone fails to capture the severity of obesity-related complications and mortality risk in Asian populations.

Do not rely on BMI alone. Ask your doctor to measure your waist circumference and assess your overall health status (blood pressure, blood sugar, etc.) using a staging system like EOSS. This provides a more accurate picture of your health risks, especially if you are Asian and have 'normal' BMI but carry weight around your midsection.

Suboptimal dietary intake (specifically low whole grains, low dairy, and high processed meats) is directly associated with approximately 80,110 new cancer cases annually in US adults, representing 5.2% of all invasive cancers.

Focus on increasing whole grain and dairy consumption while reducing processed meat intake. This specific dietary shift is estimated to prevent a substantial number of cancer cases annually, particularly colorectal cancer. Prioritize whole grains (3 servings/day) and limit processed meats to less than 0.5 oz/day.

Mechanical loading induces skeletal muscle growth primarily through myofiber hypertrophy (increase in cross-sectional area) and fascicle architectural changes (increased length and pennation angle), rather than hyperplasia (increase in fiber number).

To maximize muscle growth, focus on resistance training that creates significant mechanical load. Expect your muscle fibers to get thicker (hypertrophy) and your muscle architecture to adapt (changes in fiber length and pennation angle). Do not rely on the idea that you are creating entirely new muscle fibers (hyperplasia), as evidence for this is weak and controversial.

Single oral doses of 150–900 mg naringenin (from whole orange extract) are safe and well-tolerated in healthy adults, with serum concentrations proportional to the dose.

Taking 300mg of naringenin (from a whole orange extract) twice daily is predicted to reach effective levels (8 μM) in your body to potentially support metabolic health, and it is safe to do so. You cannot get these levels from drinking orange juice alone.

In patients with type 2 diabetes or prediabetes and established cardiovascular risk, maintaining a BMI of 25–35 kg/m² (overweight to mild obesity) is associated with lower all-cause and cardiovascular mortality compared to a normal BMI of 22–24.9 kg/m².

If you have diabetes or prediabetes along with other heart disease risks, do not aggressively pursue weight loss to reach a 'normal' BMI (22-25). Your data suggests you are safest in the overweight to mild obesity range (BMI 25-35). Focus on cardiovascular health markers rather than the scale number.

Metabolic surgery reduces the 10-year risk of major adverse cardiovascular events (all-cause mortality, coronary artery events, heart failure, and nephropathy) in patients with type 2 diabetes and obesity compared to usual care, as quantified by the Individualized Diabetes Complications (IDC) Risk Scores.

If you have type 2 diabetes and obesity, ask your doctor about using a risk calculator (like the IDC Risk Scores) to compare your 10-year risk of heart failure, kidney disease, and death with current medications versus metabolic surgery. The data suggests surgery may significantly lower these risks for many patients, helping you make an informed decision based on your specific health profile.

Obesity without metabolic syndrome ('metabolically healthy obesity') significantly increases the 5-year cumulative incidence of hypertension and diabetes compared to lean subjects without metabolic syndrome.

If you are overweight or obese, even if your current blood pressure and blood sugar are normal, you are at a significantly higher risk of developing hypertension and diabetes within five years compared to someone of normal weight. You should not assume 'normal labs' mean 'no risk.'

Hyperuricemia is an independent risk factor for developing hypertension and diabetes, with every 1 mg/dL increase in serum uric acid increasing the risk of hypertension by 19% and diabetes by 27%.

High uric acid is not just about gout; it independently raises your risk of high blood pressure and diabetes. If your uric acid is high, addressing it (often through diet, specifically reducing fructose and purines) may help prevent these conditions.

Higher circulating levels of docosahexaenoic acid (DHA) are inversely associated with the risk of incident atherothrombotic stroke, while higher levels of docosapentaenoic acid (DPA) are inversely associated with cardioembolic stroke.

If you are concerned about stroke risk, maintaining healthy levels of specific omega-3 fatty acids like DHA and DPA may be beneficial. DHA appears to help prevent strokes caused by atherosclerosis (plaque buildup), while DPA may help prevent strokes caused by heart rhythm issues like atrial fibrillation. Since EPA did not show a significant association in this study, focusing on a balanced intake of all long-chain omega-3s through diet (fatty fish) or high-quality supplements is advisable, rather than relying on a single type.

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (including muscle) and bone density, with muscle loss accounting for approximately 20% of total weight reduction in the absence of structured resistance training.

If you are taking GLP-1s for weight loss, you must incorporate resistance training (weight lifting or bodyweight exercises) at least 2-3 times per week. Without this, roughly 20% of the weight you lose will be muscle, not just fat. Ensure you are eating enough protein to support muscle retention during the caloric deficit.